Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Background The prophylactic vaccination of COVID-19 mRNA vaccines is the first large-
scale application of this kind in the human world. Over 1.8 million doses of the COVID-19 …

Background Synthesising evidence on the long-term vaccine effectiveness of COVID-19
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …

The emergence of SARS-CoV-2 has led to the infection of many people across the globe,
over six million deaths, and has placed an unprecedented burden on public health …

Background Using data from electronic health registries, this study intended to estimate the
COVID-19 vaccine effectiveness (VE) in the population aged 65 years and more, against …

Abstract The coronavirus disease 2019 (COVID-19) has been shown to have more severe
health outcomes in older people specifically in relation to mortality and disability …

COVID-19 vaccines protect against severe COVID-19–associated outcomes, including
hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness …

COVID-19 vaccines from multiple manufacturers are needed to cope with the problem of
insufficient supply. We did two single-center, randomised, double-blind, placebo-controlled …

The current study systematically reviewed, summarized and meta-analyzed the clinical
features of the vaccines in clinical trials to provide a better estimate of their efficacy, side …

Nowadays, the vaccination with COVID-19 vaccines is being promoted worldwide,
professionals and common people are very concerned about the efficacy and safety of …